Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Lactic Acid  (Biodegradable Polymer, Food & ... & Forecasts to 2019" report to their ... hydroxyl-carboxylic acid with an asymmetrical carbon atom. The ... biodegradable polymer, food and beverage, personal care product, ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... and medical device industries, has announced a laboratory and ... has consolidated its histology and tissue analysis operations from ... just north of Denver. The new addresses are: ... Suite 100, Westminster, CO 80021 , Tissue Image Analysis ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2
... June 10, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... financial results for the fourth quarter and fiscal year of ... Fourth Quarter of Fiscal 2011 Highlights Revenue ...
... 10, 2011 Sono-Tek Corporation (OTCQB: SOTK) today announced ... on Monday June 13, 2011, a scientific paper titled: ... Agents," at the Institute of Food Technologists, 2011 Annual ... annual event gathers thousands of professional experts from all ...
... Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ) today ... stockholders held on June 8, 2011. (Logo: ... of stockholders, the following directors were elected to serve ... meeting of stockholders:  John Barratt, Brian McGee, Nola Masterson, ...
Cached Biology Technology:China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 10Sono-Tek to Present Scientific Paper on Food Safety at the IFT, as E. Coli Outbreak Affects Europe's Food Supply 2Generex Announces Results of Annual Stockholders' Meeting 2Generex Announces Results of Annual Stockholders' Meeting 3Generex Announces Results of Annual Stockholders' Meeting 4
(Date:8/27/2014)... Using functional near infrared spectroscopy (fNIRS), Kessler Foundation ... people with multiple sclerosis (MS) and healthy controls. ... brain activation was studied using fNIRS while participants ... cognition using functional near infrared spectroscopy (fNIRS) in ... by Brain Imaging and Behavior . Authors ...
(Date:8/27/2014)... Many African-Americans may not be getting effective doses of ... Hopkins suggests. The initial dosing studies, completed before the ... generally lack a protein that is key to removing ... people with maximum levels of the protein including ... maraviroc in their bodies compared to those who lack ...
(Date:8/27/2014)... found in forests has created a thriving habitat for ... new University of Georgia study has found. , Japanese ... the early 1900s, is one of the most pervasive ... dozen states in the past century, particularly in the ... can survive in widely diverse ecosystems and has been ...
Breaking Biology News(10 mins):Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... WORCESTER, Mass. Small, mobile sequences of DNA left ... their ability to move around the genome, pose a significant ... Considered genetic parasites, these transposable elements are believed to comprise ... of the damage transposons can do to an organism,s DNA, ...
... a simple, paper-based test for drug-resistant tuberculosis (TB) is ... chemist, whose project just received a $1.6 million point-of-care ... initiative created by the Bill & Melinda Gates Foundation. ... minds across scientific disciplines to work on solutions that ...
... the process of officially recognizing new plant species, botanists ... of new species, and publication in online academic journals ... publication. The new rules, which were approved at ... Botanical Congress in July, become effective January 1, 2012. ...
Cached Biology News:Defending the genome 2Defending the genome 3University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis 2Ave Atque Vale: Botany bids 'hail and farewell' to Latin-only descriptions in 2012 2Ave Atque Vale: Botany bids 'hail and farewell' to Latin-only descriptions in 2012 3
... Ham's F-12 was developed for culturing hybrid ... The modification consists of doubling the amino ... The salt concentrations have been altered as ... sulfate per liter, which may render it ...
... peptide whose sequence corresponds to residues 1-18 from rat rab 3D. ... M(1) - A - S - A - S - E ... R - D - A - A - D - Q ... and control experiments with the polyclonal antibody that reacts with this ...
... Bisulfite Kit enables complete conversion of ... than 6 hours. The highly sensitive ... DNA degradation and a spin-column-based purification ... and reliable results for all downstream ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: